Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(1.15) per share which beat the analyst consensus estimate of $(3.02) by 61.92 percent. This is a 96.78 percent increase over losses of $(35.75) per share from the same period last year. The company reported quarterly sales of $6.50 million which beat the analyst consensus estimate of $6.23 million by 4.28 percent. This is a 25.88 percent decrease over sales of $8.77 million the same period last year.